Golgi Neurosciences and Breye Therapeutics announce successful closing of P2X7 receptor antagonist program transfer
Milan, Italy and Copenhagen, Denmark, July 25th 2023 – Golgi Neurosciences S.r.l. and Breye Therapeutics ApS, a clinical-stage biopharmaceutical company developing novel oral therapies for retinal vascular diseases within ophthalmology, are thrilled to announces a collaboration to develop the P2X7 receptor antagonist program. The collaboration aims to develop a novel approach for the treatment of both early-stage DR and dry-AMD, disorders with a large unmet medical need for more effective and less burdensome therapies.
Read the Press Release
